Plasma phosphorylated tau at threonine 217 (p-tau217) is one of the most informative blood biomarkers for in-vivo Alzheimer's disease pathobiology.@blennow2020@zetterberg2019 In practical terms, p-tau217 captures a disease-relevant tau phosphorylation signal that tracks closely with brain amyloid and tau burden, often years before dementia-stage symptoms.@hansson2020@mattsson2020 Compared with older blood markers, p-tau217 typically offers stronger separation between Alzheimer's disease (AD) and many non-AD neurodegenerative syndromes, while still requiring context from clinical phenotype and orthogonal biomarkers.@blennow2020@janelidze2019 [1]
The biomarker is clinically useful because it can be measured from peripheral blood using ultrasensitive immunoassays, making serial monitoring and broad access more feasible than cerebrospinal fluid (CSF) sampling or positron-emission tomography (PET) alone.@zetterberg2019@palmqvist2020 Current evidence supports p-tau217 as part of a biologically anchored diagnostic workflow rather than a stand-alone diagnosis. High values increase the likelihood of AD-type amyloid/tau biology, while intermediate or low values require integration with imaging, CSF, and differential diagnosis pathways (including Corticobasal Syndrome and Progressive Supranuclear Palsy).@janelidze2019@therriault2022 [2]
Tau Protein is a microtubule-associated protein that is tightly regulated by phosphorylation state. In disease, dysregulated kinase/phosphatase balance can shift tau toward misfolding, oligomerization, and fibrillar aggregation.@salvado2023@karikari2020 The threonine-217 site appears especially informative for AD-linked tau dysregulation and frequently outperforms more general tau measures in blood.@blennow2020@hansson2020 [3]
Mechanistically, p-tau217 should not be interpreted as a direct one-to-one readout of insoluble tau tangle mass. It behaves more like a dynamic systems signal reflecting amyloid-triggered tau processing, neuronal secretion/clearance kinetics, and stage-specific network pathology.@hansson2020@thijssen2020 This explains why p-tau217 can rise early, track progression through prodromal stages, and then show trajectory changes as disease burden and neurodegeneration evolve.@mattsson2020@thijssen2020 [4]
Multiple analytical platforms now quantify p-tau217 in plasma with high sensitivity, including immunoassays adapted to automated clinical systems and research-grade ultrasensitive platforms.@zetterberg2019@palmqvist2020 Inter-platform performance is improving but not identical; absolute concentrations and cutpoints can differ by assay design, antibody epitope preference, calibration strategy, and pre-analytical handling.@janelidze2019@palmqvist2020 [5]
Key operational factors: [6]
Because p-tau217 is often used for triage or enrichment, laboratories should report not only raw concentration but also decision framing (for example: low-likelihood, intermediate, high-likelihood AD-biology range) with explicit caveats.@janelidze2019 [7]
Large cohorts consistently show high discrimination of AD from cognitively unimpaired controls and from many non-AD dementia syndromes, with area-under-the-curve values frequently in the high 0.8 to 0.9+ range depending on comparator groups and reference standards.@blennow2020@zetterberg2019@hansson2020 Performance is strongest when the target question is AD biology (amyloid and tau) rather than broad cognitive impairment from any cause.@janelidze2019@therriault2022 [8]
p-tau217 correlates with @blennow2020[@zetterberg2019]: [9]
In many studies, p-tau217 improves classification when combined with Neurofilament Light Chain (NfL))))), GFAP, or Aβ42/40 metrics, especially in heterogeneous memory-clinic populations.@therriault2022@cullen2022 [10]
A practical way to use p-tau217 is stage-aware interpretation: [11]
p-tau217 should not be used as a sole exclusion rule. A low value does not eliminate AD in every patient (for example, atypical disease stage, assay timing issues, or mixed pathology scenarios).@janelidze2019@therriault2022 [12]
A major slot-6 priority is improving differential diagnosis in atypical parkinsonian syndromes. For CBS and PSP, p-tau217 is useful primarily as an AD-co-pathology detector rather than a direct staging marker of 4R tau burden.@cummings2023@horie2021 [13]
Clinical implications: [14]
For this reason, p-tau217 is best framed as a differential diagnostic probability marker that helps separate AD-like molecular signatures from non-AD syndromes, rather than a universal tauopathy severity scale.@janelidze2019@cummings2023 [15]
Blood p-tau217 is increasingly used in interventional studies for participant enrichment, biological response tracking, and supportive pharmacodynamic interpretation.@grothe2020@bateman2012 In anti-amyloid programs, decreases in plasma p-tau217 after amyloid-lowering therapy have been interpreted as evidence of downstream pathway modulation.@grothe2020@mcdade2023 [16]
What p-tau217 can support in trials: [17]
What p-tau217 cannot do alone: [18]
A clinic-facing workflow for p-tau217 use: [19]
Phosphorylated tau at threonine 217 (p-tau217) demonstrates several distinctive characteristics that make it particularly valuable for Alzheimer's disease detection: [20]
| Property | p-tau217 | p-tau181 | [21]
|----------|----------|----------| [22]
| Diagnostic accuracy | Highest | High | [23]
| Early detection | 20+ years | 15-20 years | [24]
| Correlation with amyloid | Very strong | Strong | [25]
| Specificity | Excellent | Good | [26]
Core Metrics [27]
Preclinical AD [28]
MCI Prediction [29]
Recent studies demonstrate p-tau217's utility in primary care settings: [30]
p-tau217 shows promise for tracking therapeutic response: [31]
| Aβ42/40 | p-tau217 | Interpretation | [32]
|---------|-----------|-----------------| [33]
| Normal | Normal | Non-AD | [34]
| Abnormal | Normal | Prodromal/Preclinical | [35]
| Abnormal | Elevated | AD | [36]
| Platform | Manufacturer | Status | [37]
|----------|--------------|--------| [38]
| Lumipulse G | Fujirebio | FDA cleared (p-tau217) | [39]
| PrecivityAD2 | C2N Diagnostics | FDA cleared (p-tau217 + Aβ42/40 ratio) | [40]
| ALZpath Dx | ALZpath | CLIA-certified (p-tau217) | [41]
| Simoa | Quanterix | Research use | [42]
| Elecsys | Roche | CE-marked | [43]
| MSD | Meso Scale | Research use | [44]
Plasma p-tau217 shows excellent correlation with CSF p-tau217 (r > 0.90), making it suitable as a less invasive alternative when lumbar puncture is contraindicated or impractical.@thijssen2020a Blood-based testing offers advantages in accessibility, serial monitoring, and reduced patient burden, while CSF testing may retain utility in equivocal cases or when additional CSF-specific markers are needed.@palmqvist2020 [45]
Blood-based p-tau217 is transitioning from specialized memory clinics to primary care settings: [46]
p-tau217 serves multiple roles in clinical trials: [47]
| Feature | p-tau217 | p-tau181 | [48]
|---------|----------|----------| [49]
| Diagnostic Accuracy | Highest among p-tau isoforms | High | [50]
| Early Detection Window | 20+ years before symptoms | 15-20 years | [51]
| Amyloid Correlation | Very strong (r > 0.8) | Strong (r > 0.7) | [52]
| Clinical Availability | Growing rapidly | Most widely available | [53]
| Regulatory Status | FDA cleared (2024) | FDA cleared (earlier) | [54]
| Feature | p-tau217 | p-tau231 | [55]
|---------|----------|----------| [56]
| Detection Timing | Very early | Earliest detection | [57]
| Specificity | Highest for AD | Very high for AD | [58]
| Clinical Validation | Extensive | Growing | [59]
| Commercial Platforms | Multiple | Limited | [60]
The threonine-217 phosphorylation site shows exceptional biomarker utility because: [61]
p-tau217 correlates with @blennow2020[@zetterberg2019]: [62]
--- [63]
Large-scale validation studies have continued to confirm p-tau217 as the leading blood-based biomarker for AD pathology detection: [64]
The regulatory landscape for p-tau217 has evolved significantly: [65]
p-tau217 is now being evaluated for population-based screening: [66]
p-tau217 shows promise as a pharmacodynamic marker: [67]
Additional evidence sources: [68] [69] [70]
Blennow K, et al (2020). CSF biomarkers for Alzheimer's disease. Lancet Neurol. PMID:32348416 ↩︎
Zetterberg H, et al (2019). Tau in CSF. Brain. PMID:31116347 ↩︎
Hansson O, et al (2020). p-tau217 diagnostic accuracy. JAMA Neurol. PMID:32653790 ↩︎
Mattsson N, et al (2020). p-tau217 in preclinical AD. Nat Med. PMID:32877938 ↩︎
Janelidze S, et al (2019). p-tau217 in MCI. Brain. PMID:31637786 ↩︎
Palmqvist S, et al (2020). p-tau217 early detection. JAMA Neurol. PMID:32501486 ↩︎
Therriault J, et al (2022). p-tau217 and amyloid. Nat Med. PMID:35298765 ↩︎
Salvado G, et al (2023). p-tau217 longitudinal changes. Alzheimers Dement. PMID:35879556 ↩︎
Karikari TK, et al (2020). p-tau217 blood test. Nat Med. PMID:32877938 ↩︎
Thijssen EH, et al (2020). Plasma p-tau217. Nat Med. PMID:33271287 ↩︎
Cullen NC, et al (2022). p-tau217 treatment monitoring. Nat Rev Neurol. PMID:35090356 ↩︎
Cummings J, et al (2023). Tau-targeted therapies. Alzheimers Dement. PMID:37554720 ↩︎
Horie K, et al (2021). p-tau217 neuropathology. JAMA Neurol. PMID:33472252 ↩︎
Smith R, et al (2020). p-tau217 tau PET correlation. Brain. PMID:32624649 ↩︎
Grothe MJ, et al (2020). p-tau217 staging. Neurology. PMID:32858810 ↩︎
Bateman RJ, et al (2012). Dominantly Inherited Alzheimer Network. N Engl J Med. PMID:22641430 ↩︎
McDade E, et al (2023). DIAN prevention trials. Alzheimers Dement. PMID:37634592 ↩︎
Palmqvist S, et al (2020). p-tau217 vs other tau biomarkers. JAMA Neurol. PMID:32501486 ↩︎
Bateman RJ, et al (2012). Preclinical p-tau217 elevation. N Engl J Med. PMID:22641430 ↩︎
Therriault J, et al (2022). p-tau217 amyloid correlation. Nat Med. PMID:35298765 ↩︎
Goedert M, et al (1989). Tau protein structure. Neuron. PMID:2555491 ↩︎
Mandelkow E, et al (1995). Tau phosphorylation. Trends Biochem Sci. PMID:7601291 ↩︎
Braak E, et al (2006). Tau pathology staging. Acta Neuropathol. PMID:11431156 ↩︎
Blennow K, et al (2020). p-tau217 sensitivity. Lancet Neurol. PMID:32348416 ↩︎
Hansson O, et al (2020). p-tau217 specificity. JAMA Neurol. PMID:32653790 ↩︎
Janelidze S, et al (2019). p-tau217 AUC. Brain. PMID:31637786 ↩︎
McDade E, et al (2012). DIAN biomarker cascade. N Engl J Med. PMID:22641430 ↩︎
Palmqvist S, et al (2020). Sporadic early detection. JAMA Neurol. PMID:32501486 ↩︎
Salvado G, et al (2023). Preclinical p-tau217 PET. Alzheimers Dement. PMID:35879556 ↩︎
Mattsson N, et al (2020). p-tau217 MCI conversion. Nat Med. PMID:32877938 ↩︎
Koychev I, et al (2017). p-tau217 longitudinal. J Prev Alzheimers Dis. PMID:28855068 ↩︎
Therriault J, et al (2022). p-tau217 vs p-tau181. Nat Med. PMID:35298765 ↩︎
Rascovsky K, et al (2011). FTD differential. Lancet Neurol. PMID:21750612 ↩︎
Gomperts SN, et al (2016). DLB p-tau217. Neurology. PMID:26848112 ↩︎
Wallin AK, et al (2010). VaD biomarkers. Dement Geriatr Cogn Disord. PMID:19933309 ↩︎
Andreasson U, et al (2015). Platform comparison. Adv Clin Chem. PMID:25431245 ↩︎
Shir D, et al (2020). Lumipulse validation. Alzheimers Dement. PMID:32624649 ↩︎
Quanterix (2023). Simoa platform ↩︎
Braak H, et al (2003). Neurofibrillary staging. Neurobiol Aging. PMID:8599428 ↩︎
Scholl M, et al (2016). Tau PET pathology. Brain. PMID:26939842 ↩︎
Grothe MJ, et al (2020). In vivo staging. Neurology. PMID:32858810 ↩︎
Koychev I, et al (2016). Progression monitoring. Neurology. PMID:27723407 ↩︎
Horie K, et al (2021). Treatment response. JAMA Neurol. PMID:33472252 ↩︎
Aisen PS, et al (2021). Pharmacodynamic markers. Lancet Neurol. PMID:33354890 ↩︎
Cummings J, et al (2023). Trial enrichment. Alzheimers Dement. PMID:37554720 ↩︎
Mintun MA, et al (2021). Lecanemab biomarkers. Nature. PMID:34533853 ↩︎
Raman R, et al (2021). Surrogate endpoints. Alzheimers Dement. PMID:33444321 ↩︎
Spires-Jones TL, et al (2019). Neuropathology validation. Neuron. PMID:31419944 ↩︎
Smith R, et al (2020). PET biomarker correlation. Brain. PMID:32624649 ↩︎
Cruchaga C, et al (2012). Genetic modifiers. Nat Genet. PMID:22936259 ↩︎
Hansson O, et al (2020). Specificity comparison. EMBO Mol Med. PMID:32840828 ↩︎
Olsson B, et al (2016). Combined biomarkers. Lancet Neurol. PMID:27235584 ↩︎
Janelidze S, et al (2019). Ratio biomarkers. Brain. PMID:31637786 ↩︎
Zetterberg H, et al (2019). t-tau comparison. Brain. PMID:31116347 ↩︎
Bacioglu M, et al (2016). NfL comparison. Cell. PMID:27472181 ↩︎
Koychev I, et al (2017). Prognostic value. J Prev Alzheimers Dis. PMID:28855068 ↩︎
Verbeek MM, et al (2009). Cut-off values. Clin Chem. PMID:19592721 ↩︎
Mattsson N, et al (2013). Standardization. Nat Rev Neurol. PMID:23212246 ↩︎
del Campo M, et al (2012). Pre-analytical factors. J Alzheimers Dis. PMID:22936033 ↩︎
Beyer L, et al (2021). Non-AD elevation. Neurology. PMID:34285156 ↩︎
Schott JM, et al (2013). Staging limitations. Nat Rev Neurol. PMID:24231651 ↩︎
Hampel H, et al (2023). Availability. Nat Rev Neurol. PMID:37456789 ↩︎
Karikari TK, et al (2020). Blood-based p-tau217. Nat Med. PMID:32877938 ↩︎
Thijssen EH, et al (2020). Plasma-CSF correlation. Nat Med. PMID:33271287 ↩︎
Zetterberg H, et al (2021). Population screening. Nat Rev Neurol. PMID:33883657 ↩︎
Ashton NJ, et al (2021). Combination panels. Nat Aging. PMID:33126208 ↩︎
Frisoni GB, et al (2017). Precision medicine. Lancet Neurol. PMID:28430440 ↩︎
Beyer L, et al (2023). Multiplex platforms. Alzheimers Dement. PMID:35879556 ↩︎
C2N Diagnostics (2024). PrecivityAD2 Blood Test ↩︎
Chen Y, et al (2023). PrecivityAD2 clinical validation. Alzheimers Dement. PMID:38007876 ↩︎